Hairy Cell Leukemia

Justin Watts, Martin S. Tallman

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter presents two case studies and series of question and answers on hairy cell leukemia (HCL). It commences with a discourse on how minimal residual disease (MRD) defined, and also MRD on portend relapse in HCL, and ends with the question on best front-line therapy in a symptomatic pregnant patient with HCL. The chapter also discusses on whether a patient relapses after a single cycle of cladribine and best therapeutic approach, and best treatment for patients with multiply relapsed HCL and a role for hematopoietic cell transplantation (HCT).

Original languageEnglish (US)
Title of host publicationCancer Consult: Expertise for Clinical Practice
PublisherWiley Blackwell
Pages220-225
Number of pages6
ISBN (Print)9781118589199, 9781118589212
DOIs
StatePublished - Jun 20 2014
Externally publishedYes

Fingerprint

Hairy Cell Leukemia
Residual Neoplasm
Cladribine
Recurrence
Cell Transplantation
Therapeutics

Keywords

  • Hairy cell leukemia (HCL)
  • Minimal residual disease (MRD)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Watts, J., & Tallman, M. S. (2014). Hairy Cell Leukemia. In Cancer Consult: Expertise for Clinical Practice (pp. 220-225). Wiley Blackwell. https://doi.org/10.1002/9781118589199.ch34

Hairy Cell Leukemia. / Watts, Justin; Tallman, Martin S.

Cancer Consult: Expertise for Clinical Practice. Wiley Blackwell, 2014. p. 220-225.

Research output: Chapter in Book/Report/Conference proceedingChapter

Watts, J & Tallman, MS 2014, Hairy Cell Leukemia. in Cancer Consult: Expertise for Clinical Practice. Wiley Blackwell, pp. 220-225. https://doi.org/10.1002/9781118589199.ch34
Watts J, Tallman MS. Hairy Cell Leukemia. In Cancer Consult: Expertise for Clinical Practice. Wiley Blackwell. 2014. p. 220-225 https://doi.org/10.1002/9781118589199.ch34
Watts, Justin ; Tallman, Martin S. / Hairy Cell Leukemia. Cancer Consult: Expertise for Clinical Practice. Wiley Blackwell, 2014. pp. 220-225
@inbook{848e36002d5c43c88d64ddd9b2078b0c,
title = "Hairy Cell Leukemia",
abstract = "This chapter presents two case studies and series of question and answers on hairy cell leukemia (HCL). It commences with a discourse on how minimal residual disease (MRD) defined, and also MRD on portend relapse in HCL, and ends with the question on best front-line therapy in a symptomatic pregnant patient with HCL. The chapter also discusses on whether a patient relapses after a single cycle of cladribine and best therapeutic approach, and best treatment for patients with multiply relapsed HCL and a role for hematopoietic cell transplantation (HCT).",
keywords = "Hairy cell leukemia (HCL), Minimal residual disease (MRD)",
author = "Justin Watts and Tallman, {Martin S.}",
year = "2014",
month = "6",
day = "20",
doi = "10.1002/9781118589199.ch34",
language = "English (US)",
isbn = "9781118589199",
pages = "220--225",
booktitle = "Cancer Consult: Expertise for Clinical Practice",
publisher = "Wiley Blackwell",

}

TY - CHAP

T1 - Hairy Cell Leukemia

AU - Watts, Justin

AU - Tallman, Martin S.

PY - 2014/6/20

Y1 - 2014/6/20

N2 - This chapter presents two case studies and series of question and answers on hairy cell leukemia (HCL). It commences with a discourse on how minimal residual disease (MRD) defined, and also MRD on portend relapse in HCL, and ends with the question on best front-line therapy in a symptomatic pregnant patient with HCL. The chapter also discusses on whether a patient relapses after a single cycle of cladribine and best therapeutic approach, and best treatment for patients with multiply relapsed HCL and a role for hematopoietic cell transplantation (HCT).

AB - This chapter presents two case studies and series of question and answers on hairy cell leukemia (HCL). It commences with a discourse on how minimal residual disease (MRD) defined, and also MRD on portend relapse in HCL, and ends with the question on best front-line therapy in a symptomatic pregnant patient with HCL. The chapter also discusses on whether a patient relapses after a single cycle of cladribine and best therapeutic approach, and best treatment for patients with multiply relapsed HCL and a role for hematopoietic cell transplantation (HCT).

KW - Hairy cell leukemia (HCL)

KW - Minimal residual disease (MRD)

UR - http://www.scopus.com/inward/record.url?scp=84946426426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946426426&partnerID=8YFLogxK

U2 - 10.1002/9781118589199.ch34

DO - 10.1002/9781118589199.ch34

M3 - Chapter

SN - 9781118589199

SN - 9781118589212

SP - 220

EP - 225

BT - Cancer Consult: Expertise for Clinical Practice

PB - Wiley Blackwell

ER -